Prior view was FY23 organic sales growth ‘at least’ high single digits. Abbott now projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, to be in the low double-digits and COVID-19 testing-related sales of approximately $1.3B vs. prior view of approximately $1.5B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott (NYSE: ABT) Stock Gains on Q2 Beat; Lifts 2023 Revenue Forecast
- Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
- Notable companies reporting before tomorrow’s open
- Senseonics initiated with an Underperform at Jefferies
- Stereotaxis says patient treated with Ensite X EP System with RMN System